Market growth is attributed to the high prevalence of infectious diseases, growing support for vaccine R&D, investments into vaccine development, and a rising focus on immunization. The base year considered for the Vaccines Market Research study is 2017, and the forecast has been provided for the period between 2018 and 2023.
Attractive Opportunities in Vaccines Market
The report has been segmented, on the basis of disease,Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue. The US FDA has licensed several vaccines to prevent infections, such as BioThrax (Emergent BioSolutions Inc., US) for the prevention of anthrax; Diphtheria & Tetanus Toxoids Adsorbed (Sanofi Pasteur Ltd., France); KINRIX (GlaxoSmithKline plc., UK) for immunization against diphtheria, tetanus, pertussis, and poliomyelitis; PedvaxHIB (Merck & Co., US) for diseases caused by Haemophilus influenza type B; and Afluria (CSL Limited, Australia) for the prevention of influenza.
Breakdown of Primary Interviews for Vaccines Market
The report has been segmented, on the basis of technology, conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The market for conjugate vaccine is expected to grow at the highest CAGR between 2018 and 2023. The large share of this segment can primarily be attributed to the increasing government support and rising company investments for conjugate vaccine development.
Monovalent vaccines drive the growth of market:
Monovalent Vaccines
A monovalent vaccine is designed to combat a single disease and therefore contains a single strain of an antigen. A number of monovalent vaccines for diseases, such as malaria, Ebola, and dengue are undergoing clinical trials for testing their safety and efficacy. The growing prevalence of these diseases across the globe is a major factor driving market growth.
Vaccines Market by Type
Multivalent Vaccines
A multivalent vaccine is designed to immunize against several strains or microorganisms, and therefore contains two or more strains/serotypes of the same antigen. Several combined multivalent vaccines are available in the market to protect against DTP, polio, and hepatitis, among other diseases.
Vaccines Market by Region
The market of vaccines in Asia is expected to grow at the highest CAGR during the forecast period. Asia is the fastest-growing market for vaccines. Increasing investments by companies in emerging countries, such as India and China is contributing to the growth of the market.
Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC (US), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi Pasteur (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new products in the market.
Read More about Vaccines Market:
https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html
